Roche’s Enspryng approved for Neuromyelitis Optica Spectrum Disorder

18th August 2020 Uncategorised 0

Enspryng is the first approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology

More: Roche’s Enspryng approved for Neuromyelitis Optica Spectrum Disorder
Source: News